You are here:

lomitapide (Lojuxta)

Advice

in the absence of a submission from the holder of the marketing authorisation:

lomitapide (Lojuxta®) is not recommended for use within NHS Scotland.

Indication under review: Adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).

Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.
 

Drug Details

Drug Name: lomitapide (Lojuxta)
SMC Drug ID: 956/14
Indication: Adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH).
BNF Category:
Sub Category: 2.12 Lipid-regulating drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 10 February 2014

Back